Landmark mRNA Drug Shows Promise in Preventing Deadly Melanoma Recurrence

An experimental melanoma drug, "intisomeran autogene," developed by Merck and Moderna, has demonstrated significant success in preventing the deadly skin cancer from returning. The drug utilizes messenger RNA (mRNA) technology, the same platform behind COVID-19 vaccines.

“

results represent a landmark moment for adjuvant melanoma treatment

In a large-scale Phase 3 clinical trial involving 1,137 patients, the mRNA drug, when administered alongside the immunotherapy drug pembrolizumab (the current standard of care), significantly reduced the recurrence of melanoma. It also prevented the cancer from spreading to other organs. This combination therapy represents a potential new paradigm in adjuvant melanoma treatment, aiming to help patients remain cancer-free for longer periods.

“

Intisomeran in combination with pembrolizumab has the potential to establish a new treatment paradigm in the adjuvant melanoma setting, helping patients remain cancer-free for longer

Researchers have been exploring mRNA treatments for cancer, and this marks the first time such a therapy has shown positive results in a Phase 3 trial. The treatment works by analyzing a patient's tumor to identify its unique mutational signature. mRNA technology then uses synthetic molecular instructions to teach the body how to fight these specific cancer cells. The companies are preparing to present their data at an upcoming international conference and begin the process of seeking regulatory approval.

“

Together with Merck, we are now studying intismeran in combination with pembrolizumab and other anti-cancer therapies, and as a monotherapy, across multiple tumour types and stages of disease, including melanoma, lung, bladder and kidney cancers